These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24627483)

  • 21. Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
    Kao C; Chao A; Tsai CL; Lin CY; Chuang WC; Chen HW; Yen TC; Wang TH; Lai CH; Wang HS
    Cell Death Dis; 2013 Feb; 4(2):e512. PubMed ID: 23449448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the ubiquitin-proteasome pathway in cancer therapy.
    Ishii Y; Waxman S; Germain D
    Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
    Yang Y; Gao Y; Huang J; Yang Z; Luo H; Wang F; Xu J; Cui Y; Ding H; Lin Z; Zhai X; Qu Y; Zhang L; Liu T; Ye L; Niu T; Zheng Y
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
    Liu L; Fu Y; Zheng Y; Ma M; Wang C
    Phytomedicine; 2020 Nov; 78():153312. PubMed ID: 32866906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
    Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
    Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
    Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
    [No Abstract]   [Full Text] [Related]  

  • 30. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
    Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
    Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
    Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
    Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
    J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
    Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS
    Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of proteasome subunit beta type 6 (PSMB6) associated with deltamethrin resistance in mosquitoes by proteomic and bioassay analyses.
    Sun L; Ye Y; Sun H; Yu J; Zhang L; Sun Y; Zhang D; Ma L; Shen B; Zhu C
    PLoS One; 2013; 8(6):e65859. PubMed ID: 23762443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
    J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
    Lee JC; Ahn KS; Jeong SJ; Jung JH; Kwon TR; Rhee YH; Kim SH; Kim SY; Yoon HJ; Zhu S; Chen CY; Kim SH
    J Cell Biochem; 2011 Jun; 112(6):1552-62. PubMed ID: 21344490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.